Orient Bio

Orient Bio EPS Growth

The EPS Growth of Orient Bio (002630.KS) as of Oct 29, 2026 is 65.39 %. In the previous year, EPS Growth was -202.52 % — a change of -132.29% (higher).

EPS Growth

65.39 %

YoY

-132.29%

Last updated:

EPS Growth of Orient Bio is 2026 65.39 % . EPS Growth of Orient Bio was 2025 -202.52 % . It decreases by -132.29% higher compared to the previous year.

The Orient Bio EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2019
-35.85 KRW
Jan 1, 2020
52.10 KRW
Jan 1, 2021
-40.37 KRW
Jan 1, 2022
323.88 KRW
Jan 1, 2023
-136.33 KRW
Jan 1, 2024
203.60 KRW
Jan 1, 2025
-202.52 KRW
Jan 1, 2026
65.39 KRW
The Orient Bio EPS Growth history
YEAREPS GrowthYoY
65.39 %-132.29%
-202.52 %-199.47%
203.60 %-249.35%
-136.33 %-142.09%
323.88 %-902.29%
-40.37 %-177.48%
52.10 %-245.33%
-35.85 %-180.70%
44.43 %-108.48%
-523.72 %+197.86%
-175.83 %-315.25%
81.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

EPS Growth of Orient Bio is 65.39 % in 2026.

On Eulerpool you can find the complete historical development of EPS Growth Orient Bio since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Orient Bio

All Key Metrics — Orient Bio